Guilherme Rossi
Clinical Researcher in Psychopharmacology
Papers
Trials
Key Impact
Notable for leading and co‑authoring pilot randomised and feasibility trials of ayahuasca and observational studies that advance clinical and safety knowledge of psychedelic use for anxiety, social cognition and substance use.
Background & Research
Guilherme Rossi is a clinical researcher active in contemporary psychedelic science, with a focus on translational and early‑phase clinical studies of ayahuasca and other serotonergic compounds. He has collaborated extensively with established investigators in Brazil and internationally (including J.M. Mendes Rocha, J.C. Bouso and J.E.C. Hallak), contributing to proof‑of‑concept randomised controlled trials, single‑dose feasibility studies and cross‑sectional research exploring psychometric and epidemiological aspects of psychedelic use. Rossi's work spans experimental medicine in healthy volunteers and small clinical populations, emphasising safety, tolerability and measures of social and emotional cognition.
His publications and trial involvement include pilot double‑blind and single‑blind investigations of ayahuasca for social anxiety disorder, studies of its effects on recognition of facial emotional expressions, a feasibility trial in college students with harmful alcohol use, and a trial probing interactive effects of ayahuasca with cannabidiol on social cognition. Rossi has also contributed to transcultural surveys assessing lifetime psychedelic use and mental health during the COVID‑19 confinement and to reviews of neural network modulation by ayahuasca, positioning his work at the intersection of clinical psychopharmacology, behavioural neuroscience and psychedelic epidemiology.